BeiGene’s Brukinsa (zanubrutinib), a potential new therapy for a rare form of lymphoma, is one of four new products on the latest list of medicines under review at the European Medicines Agency.
Enhertu (trastuzumab deruxtecan), AstraZeneca PLC/Daiichi Sankyo’s advanced HER2-positive breast cancer treatment, is also among the four.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?